Evidence map›Paper›PMID 42525198›Full record

ArticleClinical drug investigation2026

Signals of Venous Thromboembolism Risk from Drug-Drug Interactions Involving Benzodiazepines and Other Sedative Hypnotics: Self-Controlled Case Series Analyses.

Fengge Wang, Lin-Chieh Meng, Kacie Bogar, Colleen M Brensinger, Warren B Bilker, Sascha Dublin, Todd E H Hecht, John R Horn, Daniela C Moga, Michael E Thase and 2 more

Abstract read
In one paragraph

Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fengge Wang *Center for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Lin-Chieh Meng *Center for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Kacie BogarCenter for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Colleen M BrensingerCenter for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Warren B BilkerCenter for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Sascha DublinKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Todd E H HechtDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
John R HornDepartment of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.
Daniela C MogaDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
Michael E ThaseDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Brian L VanderBeekCenter for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA.
Charles E LeonardCenter for Real-World Effectiveness and Safety on Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 4 West, 105-D, Philadelphia, PA, 19104, USA. celeonar@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-5092-9657

Funding

Drug interactions involving psychoactive drugsR01AG060975 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Charles Edward Leonard · 2019 to 2026
$3.9M
NIA NIH HHS R01 AG060975
6 · The paper itself

Abstract

BACKGROUND AND

objectiveBenzodiazepines and sedative hypnotics such as zolpidem ("z-drugs") are commonly prescribed for anxiety and sleep disorders. Epidemiologic evidence links their use to increased risk of venous thromboembolism. We investigated venous thromboembolism risk among concomitant users of individual benzodiazepines/z-drugs (examined separately) with other prescription medications to generate data-driven hypotheses about drug interactions resulting in clinically meaningful harm to inform future etiologic studies of specific drug combinations.

methodsWe conducted a series of self-controlled case series studies within a 50% random sample of US Medicaid and Medicare data. Each cohort comprised person-time exposed to a benzodiazepine/z-drug, dichotomized into focal versus referent periods based on concomitant drug use versus non-use. We used conditional Poisson regression to estimate incidence rate ratios for hospital or emergency department presentation for venous thromboembolism. We generated ratios of incidence rate ratios, leveraging negative control analyses of eye drop-concomitant drug pairs, to minimize confounding by indication for the concomitant drug. We used semi-Bayes shrinkage to minimize false positives.

resultsAmong 1590 self-controlled case series studies involving 8853 individuals with venous thromboembolism, 38 (2.4%) potential drug interaction signals were identified before calibration. After adjustment for multiple testing and negative control findings, five (0.3%) signals remained, involving gabapentin combined with eszopiclone, lorazepam, clonazepam, or alprazolam, and apixaban combined with diazepam (ratio of incidence rate ratio range: 1.92-3.57). Four (80%) involved concurrent use of gabapentin, a medication largely used to treat neuropathic pain.

conclusionsMost benzodiazepine/z-drug combinations conferred no increased venous thromboembolism risk. However, concurrent use of a benzodiazepine/z-drug with gabapentin may increase the relative rate of venous thromboembolism up to 3.5-fold. As this work was hypothesis generating, a future etiologic study should confirm this potential drug interaction.

Indexed as

BenzodiazepinesHypnotics and SedativesVenous ThromboembolismAdultAgedAged, 80 and overDrug InteractionsFemaleHumansIncidenceMaleMiddle AgedRisk FactorsUnited StatesZolpidemBenzodiazepinesHypnotics and SedativesZolpidem

Identifiers

PMID42525198
PMCPMC13612668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.